Several companies, including ReGenTree, MimeTech, Oculis, and others are actively advancing treatments in the Neurotrophic Keratopathy market. < ...

In our study, favorable outcomes in treating neurotrophic keratopathy were seen in nearly two third of eyes. To the best of our knowledge, there is no study in the literature regarding the use of ...

The cost effectiveness body said that cenegermin, produced by Italian manufacturer Dompé, gives a treatment option for the rare disease neurotrophic keratitis. Affecting around five in every ...

There were 35 eyes of 33 patients, with a mean age of 68.2±19.5 years (range: 17–99 years). There were 25 men and 8 women. Median follow-up was 110 days (mean: 164.6 days; range: 30–960 days).

“N.K. stands for neurotrophic keratopathy, or neurotrophic keratitis, and it describes a condition in which the nerves that provide sensation to the surface of the eye, and specifically the ...

CSB-001 is under clinical development by Claris Biotherapeutics and currently in Phase I for Unspecified Ophthalmological Disorders.

Our research group is investigating the signalling and biological functions of GDNF neurotrophic family ligands and endoplasmic reticulum located CDNF/MANF protein families, both within and outside of ...